181 related articles for article (PubMed ID: 24595451)
1. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
[TBL] [Abstract][Full Text] [Related]
2. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
[TBL] [Abstract][Full Text] [Related]
4. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
5. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
6. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
7. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
8. Structures of heterodimeric POZ domains of Miz1/BCL6 and Miz1/NAC1.
Stead MA; Wright SC
Acta Crystallogr F Struct Biol Commun; 2014 Dec; 70(Pt 12):1591-6. PubMed ID: 25484205
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
[TBL] [Abstract][Full Text] [Related]
10. Structure of the wild-type human BCL6 POZ domain.
Stead MA; Rosbrook GO; Hadden JM; Trinh CH; Carr SB; Wright SC
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Dec; 64(Pt 12):1101-4. PubMed ID: 19052359
[TBL] [Abstract][Full Text] [Related]
11. Backbone resonance assignment of the BCL6-BTB/POZ domain.
Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
[TBL] [Abstract][Full Text] [Related]
12. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
13. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
Zacharchenko T; Kalverda AP; Wright SC
Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
[TBL] [Abstract][Full Text] [Related]
15. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
16. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
[TBL] [Abstract][Full Text] [Related]
17. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
18. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.
Lemercier C; Brocard MP; Puvion-Dutilleul F; Kao HY; Albagli O; Khochbin S
J Biol Chem; 2002 Jun; 277(24):22045-52. PubMed ID: 11929873
[TBL] [Abstract][Full Text] [Related]
19. Bcl6-dependent transcriptional repression by BAZF.
Takenaga M; Hatano M; Takamori M; Yamashita Y; Okada S; Kuroda Y; Tokuhisa T
Biochem Biophys Res Commun; 2003 Apr; 303(2):600-8. PubMed ID: 12659862
[TBL] [Abstract][Full Text] [Related]
20. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
